The total return over the past 12 months is +305.93% vs. +16.94% for the S&P 500. So far it's up +424.24% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +305.93% | +91.39% | +0.39% | +2.95% | N/A | N/A |
| Total Return CAGR | +305.93% | +91.39% | +0.39% | +2.95% | N/A | N/A |
| Revenue CAGR | +192.92% | +553.98% | +202.97% | +128.92% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
ImmunityBio, Inc. (IBRX)
| Year | Start price | End price | IBRX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.98 | $10.38 | +424.24% | +14.51% | +409.73% |
| 2025 | $2.56 | $1.98 | (22.66%) | +17.72% | (40.38%) |
| 2024 | $5.02 | $2.56 | (49.00%) | +24.89% | (73.89%) |
| 2023 | $5.07 | $5.02 | (0.99%) | +26.19% | (27.18%) |
| 2022 | $6.08 | $5.07 | (16.61%) | (18.17%) | +1.56% |
| 2021 | $13.33 | $6.08 | (54.39%) | +28.74% | (83.13%) |
| 2020 | $3.79 | $13.33 | +251.72% | +18.37% | +233.35% |
| 2019 | $1.16 | $3.79 | +226.72% | +31.22% | +195.50% |
| 2018 | $4.49 | $1.16 | (74.16%) | (4.56%) | (69.60%) |
| 2017 | $5.72 | $4.49 | (21.50%) | +21.70% | (43.20%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
